Nateglinide
Other Blood Glucose Lowering Drugs, Excl. Insulins
- Drug class
- Other Blood Glucose Lowering Drugs, Excl. Insulins
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 1
- Products on record
- 1
- FDA reports (12 mo)
- 58
Overview
Nateglinide is an active pharmaceutical ingredient in the Other Blood Glucose Lowering Drugs, Excl. Insulins group (A10BX). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| US United States | FDA | 1 | February 24, 2025 |
USUnited States· FDA
1 product
Uses
1 INDICATIONS AND USAGE Nateglinide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Limitations of Use:
Nateglinide should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. Nateglinide is a glinide indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
(1) Limitations of Use : Not for treating type 1 diabetes mellitus or diabetes ketoacidosis (1)
How to take
Drug interactions
Known interactions involving Nateglinide. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 476. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]FDA DailyMed · 0ccf9b07-3c21-48… · revised February 24, 2025 [PDF]
- [2]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.